Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2687

1.

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM.

J Clin Endocrinol Metab. 2000 Aug;85(8):2767-74.

PMID:
10946879
2.

Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.

Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C, Pagotto U, Pasquali R.

J Clin Endocrinol Metab. 2006 Oct;91(10):3970-80. Epub 2006 Jul 25.

PMID:
16868063
3.

Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.

Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U, Pasquali R.

Clin Endocrinol (Oxf). 2004 Feb;60(2):241-9.

PMID:
14725687
5.

The effects of metformin and diet on plasma testosterone and leptin levels in obese men.

Ozata M, Oktenli C, Bingol N, Ozdemir IC.

Obes Res. 2001 Nov;9(11):662-7.

6.

Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.

Wu J, Zhu Y, Jiang Y, Cao Y.

Gynecol Endocrinol. 2008 Jul;24(7):392-8. doi: 10.1080/09513590802217027.

PMID:
18608522
7.

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.

Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G.

Fertil Steril. 2008 Apr;89(4):899-906. Epub 2007 Nov 5.

PMID:
17980364
8.

The effects of a low-calorie diet or an isocaloric diet combined with metformin on sex hormones In obese women of child-bearing age.

Swora-Cwynar E, Kujawska-Łuczak M, Suliburska J, Reguła J, Kargulewicz A, Kręgielska-Narożna M, Marcinkowska E, Kanikowska A, Bielas M, Grzymisławski M, Bogdański P.

Acta Sci Pol Technol Aliment. 2016 Apr-Jun;15(2):213-220. doi: 10.17306/J.AFS.2016.2.21.

PMID:
28071011
9.

Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.

Ganie MA, Khurana ML, Nisar S, Shah PA, Shah ZA, Kulshrestha B, Gupta N, Zargar MA, Wani TA, Mudasir S, Mir FA, Taing S.

J Clin Endocrinol Metab. 2013 Sep;98(9):3599-607. doi: 10.1210/jc.2013-1040. Epub 2013 Jul 11.

PMID:
23846820
10.

The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.

Yilmaz M, Biri A, Karakoç A, Törüner F, Bingöl B, Cakir N, Tiras B, Ayvaz G, Arslan M.

J Endocrinol Invest. 2005 Dec;28(11):1003-8.

PMID:
16483179
11.

Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.

Kazerooni T, Dehghan-Kooshkghazi M.

Gynecol Endocrinol. 2003 Feb;17(1):51-6.

PMID:
12724019
12.

Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial.

Fux Otta C, Wior M, Iraci GS, Kaplan R, Torres D, Gaido MI, Wyse EP.

Gynecol Endocrinol. 2010 Mar;26(3):173-8. doi: 10.3109/09513590903215581.

PMID:
20148739
13.

Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.

Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D.

Int J Obes (Lond). 2008 Apr;32(4):692-9. Epub 2007 Dec 11.

PMID:
18071341
14.

Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.

Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS.

J Clin Endocrinol Metab. 2000 Sep;85(9):3161-8.

PMID:
10999803
15.

Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.

Loverro G, Lorusso F, De Pergola G, Nicolardi V, Mei L, Selvaggi L.

Gynecol Endocrinol. 2002 Jun;16(3):217-24.

PMID:
12192894
16.

Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome.

Toscani MK, Mario FM, Radavelli-Bagatini S, Spritzer PM.

Nutr Res. 2011 Feb;31(2):97-103. doi: 10.1016/j.nutres.2011.01.009.

17.

Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels.

Pagotto U, Gambineri A, Vicennati V, Heiman ML, Tschöp M, Pasquali R.

J Clin Endocrinol Metab. 2002 Dec;87(12):5625-9.

PMID:
12466363
18.

Serum leptin in obese women with polycystic ovary syndrome is correlated with body weight and fat distribution but not with androgen and insulin levels.

Vicennati V, Gambineri A, Calzoni F, Casimirri F, Macor C, Vettor R, Pasquali R.

Metabolism. 1998 Aug;47(8):988-92.

PMID:
9711997
19.

Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy.

Berker B, Emral R, Demirel C, Corapcioglu D, Unlu C, Kose K.

Gynecol Endocrinol. 2004 Sep;19(3):125-33.

PMID:
15697073
20.

Supplemental Content

Support Center